ShareholdingApr 28, 2026, 05:07 PM
QUCY Rebrands to Quantum Cyber N.V.; David Lazar Gains Control
AI Summary
MAINZ BIOMED N.V. (QUCY) has rebranded to Quantum Cyber N.V. and completed a $6 million private placement with David E. Lazar, resulting in Lazar becoming the controlling shareholder with over 95% of voting rights on a fully-diluted basis. The company also approved a reverse stock split, significantly increased authorized shares, and underwent substantial board and officer changes, including the resignation of four directors and the Co-CEO, and the appointment of two new directors.
Key Highlights
- Company rebranded from Mainz Biomed N.V. to Quantum Cyber N.V.
- David E. Lazar became controlling shareholder with over 95% of voting rights on a fully-diluted basis.
- Completed a $6 million private placement of preferred shares with David E. Lazar.
- Second Closing Shares (Series D, E Preferred) were issued on April 22, 2026, for $3 million.
- Shareholders approved a reverse stock split.
- Authorized Ordinary Shares increased from 45,000,000 to 900,000,000.
- Four directors resigned, and Co-Chief Executive Officer Guido Baechler resigned.
- David Natan and Avraham Ben-Tzvi were appointed as new directors.